Jin Shan, Yang Yun-Tian, Bao Wuyuntu
Affiliated Hospital of Inner Mongolia Medical University, Hohhot, China.
Affiliated Hospital of Inner Mongolia Medical University, Hohhot, China.
Vitam Horm. 2018;106:501-515. doi: 10.1016/bs.vh.2017.05.002. Epub 2017 Jun 19.
The morbidity of thyroid cancer is increasing gradually year by year, showing an increasing tendency in nationality, sex, age, tumor size, and tumor staging. The changes of thyroid cell genes, signaling pathways, and related molecular dysfunction promote the occurrence, development, invasion, and metastasis of thyroid cancer. Surgical operation, radioiodine, and endocrinotherapy models can achieve a better prognosis for most patients with thyroid cancer. Although targeted therapeutic drugs bring possible therapeutic opportunities for refractory thyroid cancer, there is a great gap between their predictive value and their actual efficacy. Currently, there is still no completely effective drug for the treatment. Based on the signaling pathways, the "reclaim therapy" for residual tumor and systemic intervention aims to increase anticancer ability and to encourage new directions and thoughts in the treatment of refractory thyroid cancer.
甲状腺癌的发病率逐年逐渐上升，在种族、性别、年龄、肿瘤大小及肿瘤分期方面均呈上升趋势。甲状腺细胞基因、信号通路及相关分子功能障碍的改变促进了甲状腺癌的发生、发展、侵袭及转移。手术、放射性碘及内分泌治疗模式可使大多数甲状腺癌患者获得较好的预后。尽管靶向治疗药物为难治性甲状腺癌带来了可能的治疗机会，但其预测价值与实际疗效之间仍存在很大差距。目前，仍没有完全有效的治疗药物。基于信号通路，针对残留肿瘤的“回收疗法”及全身干预旨在提高抗癌能力，并为治疗难治性甲状腺癌带来新的方向和思路。
